Clinical and experimental obstetrics & gynecology最新文献

{"title":"Reduced Proliferative Potential with Conserved Stem/Stromal Phenotype of Human Umbilical Cord Mesenchymal Stem Cells in Placental Syndromes: A Prospective Cohort Study","authors":"Luigi Marino, Maria Antonietta Castaldi, Caterina Fulgione, Salvatore Giovanni Castaldi, Paola Manzo, Valentina Giudice, Francesca Picone, Maria Rosaria Campitiello, Mario Polichetti, Maurizio Guida, Carmine Selleri, Bianca Serio","doi":"10.31083/j.ceog5009196","DOIUrl":"https://doi.org/10.31083/j.ceog5009196","url":null,"abstract":"Background: Pathophysiology of placental syndromes is still unclear, and umbilical cord-derived mesenchymal stem cells (UC-MSCs) might play a role in the development of these syndromes. In this prospective cohort study, we evaluated proliferative abilities of two types of UC-MSCs, Wharton’s Jelly MSCs (WJ-MSCs) and cord blood MSCs (CB-MSCs), in placental syndromes. Methods: A total of 16 cord blood and umbilical cord samples were seeded and cultured until MSC growth potential exhaustion. Cumulative population doublings were employed for studying growth potential, and flow cytometry immunophenotyping for verification of mesenchymal markers. Results: In our prospective cohort study, on one hand CB-MSCs from pathological pregnancies showed a significant reduction of growth potential, on the other hand WJ-MSCs showed a trend toward higher growth potential. This trend is consistent with the well-known faster-growing phenotype of WJ-MSCs under low oxygen atmosphere. Moreover, it’s well understood that chronic hypoxia is a main feature of both intrauterine growth restriction (IUGR) and preeclampsia, thus, our data perfectly match with the well-known clinical characteristics. Conclusions: Growth potential of CB-MSCs obtained from placental syndromes tended to be reduced compared to that of MSCs from healthy pregnancies. Our results need to be confirmed in larger in vitro studies, as a higher number of CB- and WJ-MSC would better clarify pathophysiology of placental syndromes.","PeriodicalId":10312,"journal":{"name":"Clinical and experimental obstetrics & gynecology","volume":"72 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136378208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Does Vaginal Estriol or Hyaluronic Acid Facilitate Office Hysteroscopy in Peri and Postmenopause? A Prospective Cohort Study","authors":"Iwona Gawron, Rafał Baran, Kamil Derbisz, Andrzej Zmaczyński, Robert Jach, Miłosz Pietrus","doi":"10.31083/j.ceog5009194","DOIUrl":"https://doi.org/10.31083/j.ceog5009194","url":null,"abstract":"Background: Pain accompanying office hysteroscopy, possibly aggravated by urogenital atrophy, is the most common reason for its discontinuation. The aim was to evaluate the effectiveness of vaginal estriol and hyaluronic acid to facilitate the office hysteroscopy in peri and postmenopausal women. Methods: A prospective cohort study involved women aged 45–90 years subjected to office hysteroscopy. Women were assigned to three study arms: (A) 0.5 mg of estriol in vaginal cream twice daily for 10 days pre-procedure, (B) 5 mg of hyaluronic acid in vaginal gel twice daily for 10 days pre-procedure, (C) no medication. The following endpoints were compared: pain accompanying the procedure, need for cervical dilation, time of cervical passage, incidence of severe urogenital atrophy, and vaso-vagal reaction. Results: There were no significant differences between the arms in terms of pain intensity during (p = 0.93) and after the procedure (p = 0.17), need for cervical dilation (p = 0.5), cervical passage time (p = 0.1), severe urogenital atrophy (p = 0.15), and vaso-vagal reaction (p = 0.29). Conclusions: Despite unfavorable conditions in peri and postmenopausal women, cervical preparation in the above regimens did not seem to bring clinically significant benefits. Clinical Trial Registration: The study was registered under the number NCT05783479 in the Protocol Registration and Results System database (https://clinicaltrials.gov/). The database used for the study was made available in Harvard Dataverse (https://doi.org/10.7910/DVN/HSWURD).","PeriodicalId":10312,"journal":{"name":"Clinical and experimental obstetrics & gynecology","volume":"49 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136313234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic Value of Combined Detection of Serum TTR, PP13 and PLGF in Preeclampsia Patients","authors":"Ying Jiang, Caifeng Deng, Xuehua Cheng, Xiaofeng Chen","doi":"10.31083/j.ceog5009195","DOIUrl":"https://doi.org/10.31083/j.ceog5009195","url":null,"abstract":"Background: To investigate the diagnostic value of serum transthyretin (TTR), placental protein 13 (PP13) and placental growth factor (PLGF) in preeclampsia patients. Methods: Sixty cases of pregnant women with preeclampsia who were examined in our hospital from January 2020 to February 2022 were retrospectively selected as the preeclampsia group, and 40 cases of healthy pregnant women who received regular physical examination in our hospital during the same period were selected as the control group. Based on the severity of the disease, the patients were allocated into two groups: mild preeclampsia group (n = 35) and severe preeclampsia group (n = 25). The levels of Serum TTR, PP13 and PLGF were compared between the groups. The correlation between serum TTR, PP13, PLGF and the patients was also analyzed by Spearman method, and receiver operating characteristic curve (ROC) and area under the curve (AUC) was adopted to analyze the clinical value of the separate and combined detection of serum TTR, PP13, PLGF in the diagnosis of preeclampsia. Results: The levels of serum TTR, PP13, PLGF in preeclampsia group were evidently lower versus the control group (p < 0.05), and those of patients in mild preeclampsia group were markedly lower versus the control group (p < 0.05), while those in severe preeclampsia group were markedly lower versus the mild preeclampsia group and control group (p < 0.05). Serum TTR, PP13, PLGF levels in preeclampsia patients were negatively correlated with the disease progression (r = –0.332, –0.315, –0.391, p < 0.05). The AUC values of TTR, PP13, PLGF in the single diagnosis of preeclampsia and their joint diagnosis were 0.812, 0.759, 0.867, and 0.887, respectively. The area under the ROC curve of TTR, PP13, and PLGF joint diagnosis of preeclampsia was higher than that of PP13 alone (p < 0.05). Conclusions: Serum TTR, PP13, and PLGF levels of preeclampsia patients were decreased compared with those of the control group, and the decrease was more significant with the aggravation of the disease, suggesting that TTR, PP13, and PLGF could be used as indicators to predict the onset and severity of preeclampsia. The combination of the three indicators could improve the diagnostic efficiency.","PeriodicalId":10312,"journal":{"name":"Clinical and experimental obstetrics & gynecology","volume":"20 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136378207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive Value of Serum Vascular Endothelial Growth Factor Level for Postoperative Endometriosis Recurrence in Patients with Ovarian Endometriosis","authors":"Yanfen Zou, Yuan Ding","doi":"10.31083/j.ceog5009187","DOIUrl":"https://doi.org/10.31083/j.ceog5009187","url":null,"abstract":"Background: Postoperative recurrence remains a problem for endometriosis. The study aimed to study whether baseline serum vascular endothelial growth factor (VEGF) levels can predict postoperative endometriosis recurrence. Methods: We included 147 patients with ovarian endometriosis who received laparoscopic endometrioma excision and postoperative gonadotropin-releasing hormone agonist treatment with hormonal add-back therapy between 2017 and 2019 in a tertiary hospital. According to endometriosis recurrence within 2 years, the patients were divided into two groups and baseline serum VEGF level measured before the surgery were compared. Logistic regression was used to examine the association between baseline serum VEGF level and endometriosis recurrence, and the area under the receiver operating characteristic curve (AUC) was calculated to examine its predictive performance. Results: The mean age of the patients was 30.1 ± 6.0 years with a duration of dysmenorrhea of 60.3 ± 35.0 months before surgery, and the majority (88.4%) were with revised American Fertility Society (rAFS) stage III or IV. Eight (5.44%) patients had endometriosis recurrence within 2 years. Compared with patients without recurrence, patients with recurrence were significantly younger (25.9 ± 4.3 vs. 30.3 ± 6.0 years, p = 0.040) and had higher baseline serum VEGF levels (689.67 ± 127.38 vs. 547.87 ± 171.31 pg/mL, p = 0.023), but there was no difference in other baseline characteristics. Serum VEGF levels were significantly associated with endometriosis recurrence (odds ratio 1.008 per pg/mL increase, 95% confidence interval 1.001–1.014) after adjusting for other baseline characteristics. The AUC of serum VEGF levels for predicting postoperative endometriosis recurrence was 0.741 (95% confidence interval 0.594–0.887). Conclusions: Baseline serum VEGF level is an independent risk factor of postoperative endometriosis recurrence and might be useful for predicting endometriosis recurrence.","PeriodicalId":10312,"journal":{"name":"Clinical and experimental obstetrics & gynecology","volume":"47 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135107477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Application of Ligation of Internal Iliac Artery and Uterine Artery in Pernicious Placenta Previa","authors":"Lijuan Bai, Jie Lin, Qiuni Shen, Xiaodong Fu","doi":"10.31083/j.ceog5009190","DOIUrl":"https://doi.org/10.31083/j.ceog5009190","url":null,"abstract":"Backgrounds: To investigate the use of vascular ligation in the treatment of pernicious placenta previa. Methods: Clinical data from 199 patients with pernicious placenta previa were collected and divided into groups according to placenta location, placenta accretion and vessel ligation, the pregnancy outcome of each group was compared. Results: The unplanned reoperation rate was lower for the internal iliac artery ligation group than the group without internal iliac artery ligation (p < 0.05). The intraoperative bleeding volume, blood transfusion volume, and intensive care unit (ICU) admission rate were lower for the prophylactic internal iliac artery ligation group than the therapeutic ligation group (p < 0.05), and in the hysterectomy patients, intraoperative bleeding was lower in the prophylactic internal iliac artery ligation group than the therapeutic ligation group (p < 0.05). The hysterectomy rate was lower for the uterine artery ligation group than the group without uterine artery ligation (p < 0.05); and for superficial and deep placental accreta, the operation time of uterine artery ligation group was shorter than internal iliac artery ligation group, intraoperative bleeding volume, blood transfusion volume, and ICU admission rate have no significant difference, when placental penetrating implantation was performed, patients with internal iliac artery ligation were statistically more severely ill, but there was no difference in prognosis. Conclusions: Vascular ligation is an effective means of managing high-risk obstetric bleeding and helps to avoid hysterectomy and unplanned reoperation, but surgeons need to choose the appropriate ligation method to improve patient prognosis, considering the patient’s condition and his or her skills.","PeriodicalId":10312,"journal":{"name":"Clinical and experimental obstetrics & gynecology","volume":"158 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135107676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validity and Reliability of the Perinatal Grief Intensity Scale in a Chinese Clinical Sample: A Prospective Cross-Sectional Study","authors":"Jianping Xu, Shuiqin Gu, Shuihong Su","doi":"10.31083/j.ceog5009189","DOIUrl":"https://doi.org/10.31083/j.ceog5009189","url":null,"abstract":"Background: This study introduced the Perinatal Grief Intensity Scale (PGIS) and applied it to assess the reliability and validity of perinatal loss in Chinese mothers. Methods: To sinicize PGIS and cultural debugging of the scale, reliability validity was assessed in this prospective cross-sectional study. Results: The Chinese version of the PGIS contained 14 items in three dimensions: reality, confront others, and congruence. The content validity index (CVI) at the total scale level, mean scale level, and item level was 0.92, 0.909, and 0.860–1.000. Exploratory factors were identified as three metric factors with a cumulative variance contribution rate of 66.627%. The Chinese version of the Perinatal Grief Scale (PGS) was used as a calibration standard, and the correlation coefficient was 0.759. The total Cronbach’s alpha coefficient for the Chinese version of the PGIS was 0.768, with a fold-half reliability of 0.749. The scale showed good reliability and validity. Conclusions: The Chinese version of the PGIS was used as a calibration standard by exploratory factor testing, and the correlation coefficient was good, and the scale had good reliability and validity for application in China.","PeriodicalId":10312,"journal":{"name":"Clinical and experimental obstetrics & gynecology","volume":"28 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135063098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of PD-1/PD-L1 Inhibitors in Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis","authors":"Zhen-Yu Li, Zhen Zhang, Xiao-Zhong Cao, Yun Feng, Sha-Sha Ren","doi":"10.31083/j.ceog5009185","DOIUrl":"https://doi.org/10.31083/j.ceog5009185","url":null,"abstract":"Background: Compared with other subtypes, triple-negative breast cancer (TNBC) is more aggressive and has a lower survival rate with chemotherapy being the only acknowledged systemic treatment option. Recently, PD-1/PD-L1 (programmed cell death-1 and programmed death-ligand 1) inhibitors have demonstrated survival benefits in locally advanced or metastatic TNBC patients. However, the effects of PD-1/PD-L1 inhibitors in neoadjuvant chemotherapy remain controversial. Methods: Extensive literature searches were conducted in the PubMed, Embase and Cochrane databases. A pooled odds ratio (OR) with 95% confidence intervals (CI) was analyzed. Results: Seven randomized controlled trials (N = 1707) were included. PD-1/PD-L1 inhibitor chemotherapy group showed pathological complete response (pCR) benefit of 59.0% vs. 40.4% (OR 1.98, 95% CI 1.38–2.82, p < 0.001). Hematological adverse events were similar. There was no significant difference between the two groups in terms of anemia (OR 1.25, 95% CI 0.93–1.68, p = 0.14; I2 = 0%, p = 0.99) or neutropenia (OR 1.00, 95% CI 0.82–1.21, p = 0.96; I2 = 0%, p = 0.70). Conclusions: Adding PD-1/PD-L1 inhibitors to neoadjuvant chemotherapy can improve pCR rates in TNBC patients without increasing hematological toxicities. The data suggests that PD-1/PD-L1 inhibitors may be a viable option for patients with TNBC.","PeriodicalId":10312,"journal":{"name":"Clinical and experimental obstetrics & gynecology","volume":"27 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135107470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Critical Aspects of Endometrial Polyp Clinical Management: A Narrative Review","authors":"Oronzo Ruggiero Ceci, Mario Franchini","doi":"10.31083/j.ceog5009188","DOIUrl":"https://doi.org/10.31083/j.ceog5009188","url":null,"abstract":"Objective: Endometrial polyps are one of the most often diagnosed gynecological pathologic findings, affecting women from reproductive age to advanced menopause. In women of childbearing age, they can cause infertility, although a clear cause-and-effect relationship is not always evident. In postmenopausal women, endometrial polyps may manifest primarily with abnormal uterine bleeding (AUB). They are usually benign lesions, and the malignant transformation, especially in menopausal women, occurs infrequently increasing with age. The ultrasound suspicion of an endometrial polyp requires a better definition of its size, position, and nature through hysteroscopy. Hysteroscopy performed as an outpatient procedure, in addition to diagnosis may be followed by the simultaneous removal of the polyp (see &amp; treat approach). If this is not possible in an outpatient setting, polypectomy can be performed in the operating theatre by means of resectoscopy or mechanical hysteroscopic tissue removal (mHTR) system. This critical study about the management of endometrial polyps, intends to examine what is still being discussed in this regard. Mechanism: A narrative review was conducted analyzing the available literature regarding the management of endometrial polyps in infertile childbearing age and pre and postmenopausal women. Findings in Brief: There is no agreement that all endometrial polyps should be removed. Polyps <10 mm can be monitored over time. In infertile women, polypectomy is recommended because it is a possible impediment to fertilization, or for Assisted Reproductive Technology (ART) procedures, however not all studies are of agreement. For patients with polyps symptomatic of AUB, polypectomy must always be recommended. Conclusions: Following an endometrial polyp diagnosis by hysteroscopy, the decision to operate should be considered for infertile women or for those with large or symptomatic menopausal polyps. Due to the lack of clear guidelines, the decision can be postponed by adopting careful surveillance in some cases.","PeriodicalId":10312,"journal":{"name":"Clinical and experimental obstetrics & gynecology","volume":"228 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135107866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Toward Better Care of Rare Ovarian Tumors","authors":"Yasuhiko Ebina","doi":"10.31083/j.ceog5009186","DOIUrl":"https://doi.org/10.31083/j.ceog5009186","url":null,"abstract":"IMR Press is a leading publisher of open access peer-reviewed biomedical and life sciences journals. We aim to facilitate the dissemination of high-quality research in the area of biomedical science. With a long tradition and wide readership, IMR Press is dedicated to making positive contributions to academics, corporate libraries as well as to readers and authors. All the editors in IMR Press will provide the best service for researchers, allowing them to have a easy and smooth publication experience and helping maximize the impact and visibility of their research.","PeriodicalId":10312,"journal":{"name":"Clinical and experimental obstetrics & gynecology","volume":"65 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135107082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gonadotropin-Releasing Hormone Agonist Combined with Hormone Replacement Therapy Protocol Improves the Live Birth Rate in Frozen-Thawed Embryo Transfer Cycles for Patients without Endometriosis","authors":"Yu Wang, Huixia Xie, Ping Shen, Qun Lv","doi":"10.31083/j.ceog5008171","DOIUrl":"https://doi.org/10.31083/j.ceog5008171","url":null,"abstract":"Background: Whether gonadotropin-releasing hormone agonist (GnRH-a) pituitary suppression improves clinical outcomes in non-endometriosis patients undergoing frozen embryo transfer remains controversial. The objective of this study is to investigate whether GnRHa combined with hormone replacement treatment (HRT) compared to HRT alone can improve the clinical outcomes of frozen-thawed embryo transfer in patients without endometriosis. Methods: This is a retrospective cohort study. This study involved 2178 frozen-thawed embryo transfer (FET) cycles of non-endometriosis patients between January 2018 and December 2019, of these cycles, 1535 were GnRHa-HRT combined cycles and 643 were HRT alone cycles. The primary outcomes were the clinical pregnancy and live birth rates. SPSS software (version 23.0, IBM Corp., Chicago, IL, USA) was used for data analysis. Results: Single-factor analysis showed that the live birth and implantation rates -were higher in the GnRHa-HRT group than those in the HRT group (p < 0.05). The mid-to-late-term miscarriage rate in the GnRHa-HRT group was lower than that in the HRT group (p < 0.05). The rates of human chorionic gonadotropin (HCG) positivity, clinical pregnancy, early abortion, multiple pregnancy, and preterm delivery between the two groups were comparable. Multivariate logistic regression analysis showed that rate of the live birth in the GnRHa-HRT group was higher than in the HRT group (p = 0.009), and there was no significant difference in the clinical pregnancy rate between the two groups (p = 0.103). Conclusions: This large-scale retrospective study revealed that non-endometriosis women in FET cycles may benefit from the GnRHa downregulation due to increasing the live birth rate.","PeriodicalId":10312,"journal":{"name":"Clinical and experimental obstetrics & gynecology","volume":"19 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135114731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}